Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.
about
Defining the sister rat mammary tumor cell lines HH-16 cl.2/1 and HH-16.cl.4 as an in vitro cell model for Erbb2Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneityClinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare eventAnalysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomasTesting for HER2 in Breast Cancer: A Continuing Evolution.HER2/neu Immunostaining in Invasive Breast Cancer: Analysis of False Positive Factors.The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast CarcinomasFrequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma.Development of NIST standard reference material 2373: Genomic DNA standards for HER2 measurements.The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response.Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens.Potential Biomarkers in Diagnosis of Human Gastric Cancer.MicroRNA-21 Expression in Primary Breast Cancer Tissue Among Egyptian Female Patients and its Correlation with Chromosome 17 Aneusomy.Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status.Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification.Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification.Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification.Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome.Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma.Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility.Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes.Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number.Correlation of HER-2/Neu protein expression and HER2 gene amplification with clinical morphological parameters of nonsmall cell lung cancer.Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer.The HER2 gene copies per tumor cell either before or after correction for chromosome-17 correlated significantly with HER2 IHC results in epithelial ovarian cancer in a tissue microarray study.
P2860
Q21134904-46C93C15-5BC1-4F94-AB97-5E4BD58F1DF5Q24797806-183A8518-8D45-4E1C-893C-A770B1162B90Q27006811-7181D1DD-C7FC-424A-B76E-39B9BBD2B73DQ28245213-1893B107-BCB8-4621-AE93-7469A099643CQ33390513-8D7740AE-618B-4237-8833-3D42A92BBCBEQ34371749-AA19DF9D-166F-40E0-86DE-1B7D51A8242FQ34424285-A4ACED06-2BF5-448C-976E-11651161CEABQ35323892-A1BCCD8C-AEAC-4F0C-8A4A-276B4B7D113AQ35687706-5BDDF98B-0D9E-4DE5-B2AE-2297C209DEEBQ36616556-52DEF066-4377-47F6-9416-DA5F96BEFE7EQ37000037-CC79A8DE-41CC-40AD-8FED-6462E491528EQ37326072-8D191DBE-8E27-4FD5-BDAA-E332D99840F8Q37406389-E5B588AF-0721-4E7F-B183-96E6C39B2920Q38414983-86332310-9601-42B6-B69B-C452264C0CB5Q38612634-FBBDB64F-347B-4C4A-A426-F704148D9BC9Q38757877-241CA75E-5310-4954-8694-7B218AA58F54Q38854683-65AB89E9-DC6B-4DF8-8149-73955141BC87Q40135743-28EB7717-44C6-4C0B-929B-42CD2B51A711Q41133771-0CFB9340-EBCE-4BDC-A761-F10BDA9E7B7BQ41821797-BD1690C8-8091-448B-9489-87FFBC41477EQ41955766-564D45B5-61EA-4E2E-B3F4-D3A65E22F117Q42718689-967BD3D8-370C-4E87-A761-BF08BC15C697Q43963074-2714F464-7A50-40F1-A7C2-425847F7A258Q47231231-68352438-76E5-4333-B198-1CA1BE847BAAQ51056791-5C33F086-6BCE-48D2-B92B-E77AF878C7E6Q51510677-D98E1A44-7382-4039-8D4F-CE03241577E4Q52976761-67A9D89A-0C21-43BD-A7E4-5A1714673338Q53581875-4E8F6E17-FCC6-46D2-845F-7F1196E8317DQ54256014-2B059096-889A-409A-9FF3-7813454C25A8Q54313117-776B64E7-4860-4019-A5C1-368A13B911EFQ54318735-C16A0213-7051-4D23-9F89-7D66906AB37BQ54635889-5E76F71C-F9A3-470E-87A9-2BB68FC3EFFF
P2860
Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Aneusomy 17 in breast cancer: ...... ssessment of HER-2/neu status.
@en
type
label
Aneusomy 17 in breast cancer: ...... ssessment of HER-2/neu status.
@en
prefLabel
Aneusomy 17 in breast cancer: ...... ssessment of HER-2/neu status.
@en
P2093
P2860
P1433
P1476
Aneusomy 17 in breast cancer: ...... ssessment of HER-2/neu status.
@en
P2093
Barbara B Haley
Eugene P Frenkel
M Hossein Saboorian
Momin T Siddiqui
Raheela Ashfaq
Sefik Gokaslan
Sijian Wang
P2860
P2888
P304
P356
10.1038/MODPATHOL.3880505
P577
2002-02-01T00:00:00Z
P5875
P6179
1032477205